1.To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia.
Xiao Shuai ZHANG ; Bing Cheng LIU ; Xin DU ; Yan Li ZHANG ; Na XU ; Xiao Li LIU ; Wei Ming LI ; Hai LIN ; Rong LIANG ; Chun Yan CHEN ; Jian HUANG ; Yun Fan YANG ; Huan Ling ZHU ; Ling PAN ; Xiao Dong WANG ; Gui Hui LI ; Zhuo Gang LIU ; Yan Qing ZHANG ; Zhen Fang LIU ; Jian Da HU ; Chun Shui LIU ; Fei LI ; Wei YANG ; Li MENG ; Yan Qiu HAN ; Li E LIN ; Zhen Yu ZHAO ; Chuan Qing TU ; Cai Feng ZHENG ; Yan Liang BAI ; Ze Ping ZHOU ; Su Ning CHEN ; Hui Ying QIU ; Li Jie YANG ; Xiu Li SUN ; Hui SUN ; Li ZHOU ; Ze Lin LIU ; Dan Yu WANG ; Jian Xin GUO ; Li Ping PANG ; Qing Shu ZENG ; Xiao Hui SUO ; Wei Hua ZHANG ; Yuan Jun ZHENG ; Qian JIANG
Chinese Journal of Hematology 2023;44(9):728-736
		                        		
		                        			
		                        			Objective: To analyze and compare therapy responses, outcomes, and incidence of severe hematologic adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia (CML) . Methods: Data of patients with chronic phase CML diagnosed between January 2006 and November 2022 from 76 centers, aged ≥18 years, and received initial flumatinib or imatinib therapy within 6 months after diagnosis in China were retrospectively interrogated. Propensity score matching (PSM) analysis was performed to reduce the bias of the initial TKI selection, and the therapy responses and outcomes of patients receiving initial flumatinib or imatinib therapy were compared. Results: A total of 4 833 adult patients with CML receiving initial imatinib (n=4 380) or flumatinib (n=453) therapy were included in the study. In the imatinib cohort, the median follow-up time was 54 [interquartile range (IQR), 31-85] months, and the 7-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.2%, 88.4%, 78.3%, and 63.0%, respectively. The 7-year FFS, PFS, and OS rates were 71.8%, 93.0%, and 96.9%, respectively. With the median follow-up of 18 (IQR, 13-25) months in the flumatinib cohort, the 2-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.4%, 86.5%, 58.4%, and 46.6%, respectively. The 2-year FFS, PFS, and OS rates were 80.1%, 95.0%, and 99.5%, respectively. The PSM analysis indicated that patients receiving initial flumatinib therapy had significantly higher cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) and higher probabilities of FFS than those receiving the initial imatinib therapy (all P<0.001), whereas the PFS (P=0.230) and OS (P=0.268) were comparable between the two cohorts. The incidence of severe hematologic adverse events (grade≥Ⅲ) was comparable in the two cohorts. Conclusion: Patients receiving initial flumatinib therapy had higher cumulative incidences of therapy responses and higher probability of FFS than those receiving initial imatinib therapy, whereas the incidence of severe hematologic adverse events was comparable between the two cohorts.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Imatinib Mesylate/adverse effects*
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Antineoplastic Agents/adverse effects*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Pyrimidines/adverse effects*
		                        			;
		                        		
		                        			Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Benzamides/adverse effects*
		                        			;
		                        		
		                        			Leukemia, Myeloid, Chronic-Phase/drug therapy*
		                        			;
		                        		
		                        			Aminopyridines/therapeutic use*
		                        			;
		                        		
		                        			Protein Kinase Inhibitors/therapeutic use*
		                        			
		                        		
		                        	
2.Design and application of the improved atomized airway humidifier
Guoping SHEN ; Hui SUN ; Xiangjun ZHU ; Xiaoqin XU ; Jie HUANG ; Yuan SUO ; Lijun CAO ; Jun XU
Chinese Critical Care Medicine 2020;32(3):376-377
		                        		
		                        			
		                        			Airway humidification is an important treatment for tracheotomy patients. At present, the commonly used methods of humidification are atomization inhalation, intra-tracheal drip, etc., but most of them have the disadvantages of interrupted humidification, inadequate humidification, repeated exposure of airway, increased nursing workload, etc. An improved disposable atomizer was designed by the emergency department of Jiaxing First Hospital in Zhejiang Province, which solved the above problems and obtained the National Utility Model Patent of China (ZL 2014 2 0406688.9). In the traditional atomizer, a make-up pipeline is added to run through the liquid container. The replenishing pipe is connected with an external infusion device. At the end of the pipeline inside the liquid container, a buoy with a guide rod is designed to continuously add liquid and automatically control the make-up speed. The device is driven by oxygen to perform airway humidification. The design can keep sufficient airway humidification, avoid frequent addition of humidification fluid, achieve the effect of increasing humidification, reducing the occurrence of complications, increasing the comfort of patients, and reducing the workload of nursing, and has a certain clinical value.
		                        		
		                        		
		                        		
		                        	
3. Design and application of a new patient transfer device
Hui SUN ; Xiangyun ZHU ; Xiaoqin XU ; Guoping SHEN ; Yuan SUO ; Lijun CAO ; Huijie YU ; Jun XU
Chinese Critical Care Medicine 2019;31(9):1158-1159
		                        		
		                        			
		                        			 In daily medical work, most of the critically ill patients who cannot move by themselves are pulled and lifted by manpower, often relying on the cooperation of many doctors and nurses, which not only increases the risk of transfer and patients' discomfort, but also causes certain skeletal and muscle damage to the porters. The emergency department of the First Hospital of Jiaxing City, Zhejiang Province designed a kind of patient transfer device, and obtained the National Utility Model Patent (ZL 2018 2 0579844.X). The transfer device is composed of upper frame, lower frame and base. The upper frame and the lower frame are rectangular and in a horizontal position. The upper frame can slide laterally through the circular tubes which are fixed on the lower frame. The lower part of the base is provided with four universal foot brake wheels. During the usage, the booster frame facilitates the transfer of patients by the rolling and two sliding tracks of the circular tube, which can make patients move smoothly and comfortably, and reduce the working intensity of the transporter. This device has good practical value. 
		                        		
		                        		
		                        		
		                        	
4.Clinical analysis of cytomegalovirus infection after haplotype hematopoietic stem cell transplantation in children.
Hong Yu SHI ; Yi Fei CHENG ; Xiao Jun HUANG ; Yu WANG ; Pan SUO ; Lan Ping XU ; Kai Yan LIU ; Xiao Hui ZHANG ; Chen Hua YAN ; Feng Rong WANG ; Yu Qian SUN ; Shen ZHANG ; Jun KONG ; Yan Qun GAO ; Yun Xue XIE
Chinese Journal of Hematology 2019;40(5):426-428
5.Design and application of a new patient transfer device.
Hui SUN ; Xiangyun ZHU ; Xiaoqin XU ; Guoping SHEN ; Yuan SUO ; Lijun CAO ; Huijie YU ; Jun XU
Chinese Critical Care Medicine 2019;31(9):1158-1159
		                        		
		                        			
		                        			In daily medical work, most of the critically ill patients who cannot move by themselves are pulled and lifted by manpower, often relying on the cooperation of many doctors and nurses, which not only increases the risk of transfer and patients' discomfort, but also causes certain skeletal and muscle damage to the porters. The emergency department of the First Hospital of Jiaxing City, Zhejiang Province designed a kind of patient transfer device, and obtained the National Utility Model Patent (ZL 2018 2 0579844.X). The transfer device is composed of upper frame, lower frame and base. The upper frame and the lower frame are rectangular and in a horizontal position. The upper frame can slide laterally through the circular tubes which are fixed on the lower frame. The lower part of the base is provided with four universal foot brake wheels. During the usage, the booster frame facilitates the transfer of patients by the rolling and two sliding tracks of the circular tube, which can make patients move smoothly and comfortably, and reduce the working intensity of the transporter. This device has good practical value.
		                        		
		                        		
		                        		
		                        			Critical Illness
		                        			;
		                        		
		                        			Emergency Service, Hospital
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Patient Transfer/methods*
		                        			
		                        		
		                        	
6.The Taxonomic Status of Spermophilus in the Plague Area of Dingbian County, Shaanxi Province, China.
Cui Hong AN ; Bao Bao CHEN ; Suo Ping FAN ; Yang Xin SUN ; Wen LYU ; Jian Jun SHE
Biomedical and Environmental Sciences 2018;31(3):238-241
		                        		
		                        			
		                        			This study was conducted to define the taxonomic status of Spermophilus in the plague area of Dingbian County in Shaanxi Province, China, through the two-factor variance analysis of morphological characteristics, DNA barcoding, and chromosome karyotype analysis. The Spermophilus samples collected from Dingbian and Zhengxiang Baiqi Counties exhibited significant differences in their morphological measurements. All Spermophilus samples form two distinct branches in neighbor-joining (NJ) tree. One branch included the Spermophilus samples collected from Inner Mongolia, and the other branch included samples collected from the plague foci of Shaanxi Province and the Ningxia Region. The Spermophilus samples collected from Dingbian County had a chromosome number of 2n = 38 in 84.40% of all their cells. The Spermophilus species collected from the plague area of Dingbian County was categorized as Spermophilus alashanicus (S.alashamicus). The findings reported in this study are epidemiologically significant for monitoring plague in this region of west-central China.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Cytochromes b
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			DNA Barcoding, Taxonomic
		                        			;
		                        		
		                        			Electron Transport Complex IV
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			Karyotype
		                        			;
		                        		
		                        			Plague
		                        			;
		                        		
		                        			microbiology
		                        			;
		                        		
		                        			Sciuridae
		                        			;
		                        		
		                        			anatomy & histology
		                        			;
		                        		
		                        			classification
		                        			;
		                        		
		                        			genetics
		                        			
		                        		
		                        	
7.Expert consensus on prescription comment of Chinese traditional patent medicine for promoting the rational use of drugs in Beijing.
Rui JIN ; Kui-Jun ZHAO ; Gui-Ming GUO ; Bing ZHANG ; Yu-Guang WANG ; Chun-Miao XUE ; Yi-Heng YANG ; Li-Xia WANG ; Guo-Hui LI ; Jin-Fa TANG ; Li-Xing NIE ; Xiang-Lin ZHANG ; Ting-Ting ZHAO ; Yi ZHANG ; Can YAN ; Suo-Zhong YUAN ; Lu-Lu SUN ; Xing-Zhong FENG ; Dan YAN ; Null
China Journal of Chinese Materia Medica 2018;43(5):1049-1053
		                        		
		                        			
		                        			With the growth of number of Chinese patent medicines and clinical use, the rational use of Chinese medicine is becoming more and more serious. Due to the complexity of Chinese medicine theory and the uncertainty of clinical application, the prescription review of Chinese patent medicine always relied on experience in their respective, leading to the uncontrolled of clinical rational use. According to the traditional Chinese medicine (TCM) theory and characteristics of the unique clinical therapeutics, based on the practice experience and expertise comments, our paper formed the expert consensus on the prescription review of Chinese traditional patent medicine for promoting the rational use of drugs in Beijing. The objective, methods and key points of prescription review of Chinese patent medicine, were included in this expert consensus, in order to regulate the behavior of prescription and promote rational drug use.
		                        		
		                        		
		                        		
		                        	
8.Risk Factors for Anxiety in Major Depressive Disorder Patients.
Li Min XIN ; Lin CHEN ; Zhen Peng JI ; Suo Yuan ZHANG ; Jun WANG ; Yan Hong LIU ; Da Fang CHEN ; Fu De YANG ; Gang WANG ; Yi Ru FANG ; Zheng LU ; Hai Chen YANG ; Jian HU ; Zhi Yu CHEN ; Yi HUANG ; Jing SUN ; Xiao Ping WANG ; Hui Chun LI ; Jin Bei ZHANG ; Tian Mei SI
Clinical Psychopharmacology and Neuroscience 2015;13(3):263-268
		                        		
		                        			
		                        			OBJECTIVE: To analyze the sociodemographic and clinical factors related to anxiety in patients with major depressive disorder (MDD). METHODS: This study involved a secondary analysis of data obtained from the Diagnostic Assessment Service for People with Bipolar Disorders in China (DASP), which was initiated by the Chinese Society of Psychiatry (CSP) and conducted from September 1, 2010 to February 28, 2011. Based on the presence or absence of anxiety-related characteristics, 1,178 MDD patients were classified as suffering from anxious depression (n=915) or non-anxious depression (n=263), respectively. RESULTS: Compared with the non-anxious group, the anxious-depression group had an older age at onset (t=-4.39, p<0.001), were older (t=-4.69, p<0.001), reported more lifetime depressive episodes (z=-3.24, p=0.001), were more likely to experience seasonal depressive episodes (chi2=6.896, p=0.009) and depressive episodes following stressful life events (chi2=59.350, p<0.001), and were more likely to have a family history of psychiatric disorders (chi2=6.091, p=0.014). Their positive and total scores on the Mood Disorder Questionnaire (MDQ) and the 32-item Hypomania Checklist (HCL-32) (p<0.05) were also lower. The logistic regression analysis indicated that age (odds ratio [OR]=1.03, p<0.001), a lower total MDQ score (OR=0.94, p=0.011), depressive episodes following stressful life events (OR=3.04, p<0.001), and seasonal depressive episodes (OR=1.75, p=0.039) were significantly associated with anxious depression. CONCLUSION: These findings indicate that older age, fewer subclinical bipolar features, an increased number of depressive episodes following stressful life events, and seasonal depressive episodes may be risk factors for anxiety-related characteristics in patients with MDD.
		                        		
		                        		
		                        		
		                        			Anxiety*
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Bipolar Disorder
		                        			;
		                        		
		                        			Checklist
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Depression
		                        			;
		                        		
		                        			Depressive Disorder
		                        			;
		                        		
		                        			Depressive Disorder, Major*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Logistic Models
		                        			;
		                        		
		                        			Mood Disorders
		                        			;
		                        		
		                        			Risk Factors*
		                        			;
		                        		
		                        			Seasons
		                        			
		                        		
		                        	
9.Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170.
Xiaodong SUN ; Fang LI ; Bin DONG ; Shaojun SUO ; Min LIU ; Dengwen LI ; Jun ZHOU
Protein & Cell 2013;4(4):266-276
		                        		
		                        			
		                        			Angiogenesis, the expansion of preexisting blood vessels, is a complex process required for tumor growth and metastasis. Although current antiangiogenic strategies have shown promising results in several cancer types, identification of additional antiangiogenic targets is required to improve the therapeutic response. Herein, we show that the microtubule-binding protein CLIP-170 (cytoplasmic linker protein of 170 kDa) is highly expressed in breast tumor samples and correlates positively with blood vessel density. Depletion of CLIP-170 significantly impaired vascular endothelial tube formation and sprouting in vitro and inhibited breast tumor growth in mice by decreasing tumor vascularization. Our data further show that CLIP-170 is important for the migration but not the proliferation of vascular endothelial cells. In addition, CLIP-170 promotes the polarization of endothelial cells in response to the angiogenic stimulus. These findings thus demonstrate a critical role for CLIP-170 in tumor angiogenesis and suggest its potential as a novel antiangiogenic target.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Breast Neoplasms
		                        			;
		                        		
		                        			blood supply
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Cell Line, Tumor
		                        			;
		                        		
		                        			Cell Movement
		                        			;
		                        		
		                        			Cell Polarity
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Human Umbilical Vein Endothelial Cells
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			MCF-7 Cells
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Nude
		                        			;
		                        		
		                        			Microtubule-Associated Proteins
		                        			;
		                        		
		                        			antagonists & inhibitors
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Microtubules
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Neoplasm Proteins
		                        			;
		                        		
		                        			antagonists & inhibitors
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Neovascularization, Pathologic
		                        			;
		                        		
		                        			RNA Interference
		                        			;
		                        		
		                        			RNA, Small Interfering
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Transplantation, Heterologous
		                        			
		                        		
		                        	
10.Replantation of fingertip amputation in lack of availability of intravenous anastomosis.
Jian-Min WEI ; Jun-Suo SUN ; Xiao-Hu JIAO ; Dou-Xing JING ; Wei HE ; Wen-Kuo JIN ; Shi-Gao CHEN
China Journal of Orthopaedics and Traumatology 2012;25(8):648-650
OBJECTIVETo discuss the replantation of fingertip amputation in lack of availability of intravenous anastomosis.
METHODSFrom November 2009 to November 2010, 86 patients (104 fingers) with fingertip amputation were treated with replantatioin, including 64 males and 22 females, with an average age of 26 years ranging from 2 to 64 years. The time from injury to therapy was from 30 min to 12 h, time of broken finger ischemia was from 2.5 to 12 h. Preoperative examination showed no obvious abnormalities. Four different replantation methods were selectively applied to these 104 amputated fingertips of 86 cases: (1) replantation with anastomosis of single or bilateral proper digital artery in 37 fingers; (2) replantation with arteriovenous bypass in 27 fingers; (3) replantation with exclusive anastomosis of digital artery in 24 fingers; (4) replantation with removing the palmar pocket method in 16 fingers.
RESULTSOne hundred and two of 104 amputated fingertips were survived. Among these survived fingers,75 cases (92 fingers) were followed-up for 6 to 24 months. According to the assessment standard of Chinese Medical Association of Hand Surgery, the results were excellent in 52 cases, good in 19, poor in 4.
CONCLUSIONIt benefits to expand the indications and improve the survival rate of replantation of fingertip amputation with the correct choice of different replantation methods according to the injury situation of the broken fingertip artery after debridement under the microscope.
Adolescent ; Adult ; Amputation ; Child ; Child, Preschool ; Debridement ; Female ; Fingers ; physiology ; surgery ; Humans ; Male ; Middle Aged ; Recovery of Function ; Replantation ; methods ; Young Adult
            
Result Analysis
Print
Save
E-mail